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Palliative radiotherapy near the end of life
Susan Y. Wu1, Lisa Singer2, Lauren Boreta1, Michael A. Garcia1, Shannon E. Fogh1 and Steve E. Braunstein1*
Abstract
Background: A significant proportion of patients with advanced cancer undergo palliative radiotherapy (RT) within
their last 30 days of life. This study characterizes palliative RT at our institution and aims to identify patients who
may experience limited benefit from RT due to imminent mortality.
Methods: Five hundred and-eighteen patients treated with external beam RT to a site of metastatic disease between
2012 and 2016 were included. Mann-Whitney U and chi-squared tests were used to identify factors associated with RT
within 30 days of death (D30RT).
Results: Median age at RT was 63 years (IQR 54–71). Median time from RT to death was 74 days (IQR 33–174). One
hundred and twenty-five patients (24%) died within 30 days of RT. D30RT was associated with older age at RT (64 vs. 62
years, p = 0.04), shorter interval since diagnosis (14 vs. 31months, p < 0.001), liver metastasis (p = 0.02), lower KPS (50
vs. 70, p < 0.001), lower BMI (22 vs. 24, p = 0.001), and inpatient status at consult (56% vs. 26%, p < 0.001). Patients who
died within 30 days of RT were less likely to have hospice involved in their care (44% vs. 71%, p = 0.001). D30RT was
associated with higher Chow and TEACHH scores at consult (p < 0.001 for both).
Conclusions: Twenty-four percent of patients received palliative RT within 30 days of death. Additional tools are
necessary to help physicians identify patients who would benefit from short treatment courses or alternative
interventions to maximize quality at the end of life.
Keywords: Palliative radiotherapy, End-of-life care, Cancer
Summary
Over half of patients undergoing radiation are treated
with palliative intent. This study aims to characterize use
of palliative radiation therapy in patients with advanced
cancer and identify factors associated with imminent
mortality in this patient population.
Background
More than half of patients treated with radiotherapy
(RT) are treated with palliative intent. RT has
well-established utility for pain palliation from bone me-
tastases, may be used to improve neurological function
or prevent further neurological compromise in patients
with brain or spinal cord metastases, and can be used to
alleviate symptoms due to obstruction by tumor.
While the response rate to RT in the treatment of
bone metastases is high, at approximately 60% [1], the
time frame for symptomatic improvement is typically
measured in weeks [2–4]. Palliative RT for brain metas-
tases may result in stable or improved neurologic symp-
toms in about half of patients [5], however is also
associated with side effects [6] and may not improve
overall survival [7]. Patients undergoing RT at the end of
life may not experience symptomatic benefit and may
spend a significant proportion of their remaining life ex-
pectancy receiving treatment [8]. Time spent on treat-
ment at the end of life may not align with patients’ end
of life goals, particularly in the United States where sin-
gle fraction RT is less commonly utilized. Medicare data
suggests that in the United States, almost 8% of patients
dying of cancer will receive RT in their last month of
life, and almost 20% of these patients will be treated in
10 or more fractions [9, 10].
The purpose of this study is to characterize use of pal-
liative RT in patients with advanced cancer at a single
institution and identify factors associated with RT within
30 days of death (D30RT).
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Methods
Patient information
We performed a retrospective single-institution review
to identify patients who received external beam RT to a
site of metastatic disease between 2012 and 2016. Pa-
tients treated with stereotactic radiosurgery (SRS) for
limited brain metastases were excluded from this ana-
lysis as this represents a highly select group of patients;
at our institution, each case is reviewed at a weekly
multidisciplinary SRS tumor board and the treatment
decision takes into account factors such as patient per-
formance status, control of extracranial disease, and po-
tential systemic therapy options. As our patient list was
generated using ICD codes for secondary malignant neo-
plasms (196–198, C78, and C79), we also excluded pa-
tients receiving potentially palliative RT to their primary
tumor.
Patient characteristics such as age, gender, primary
diagnosis, prior chemotherapy or other systemic treat-
ment, performance status at consult, use of hospice ser-
vices, and radiation dose/fractionation were abstracted
from the medical record. In addition to clinical variables
used to calculate the TEACHH and Chow scores de-
scribed below, we also recorded BMI, as weight loss has
been shown to be a poor prognostic sign in patients with
cancer [11], and inpatient status at the time of consult
[10]. Vital status and date of death were confirmed with
our institutional tumor registry. The institutional review
board approved this retrospective review. Given the vol-
ume of individual patient data and ongoing work, this
database has not been made publicly available however
is available upon request from the corresponding author.
Prognostic scores
The TEACCH and Chow models have been described
previously [12, 13]. The Chow model of risk factors
grouping is simple to use and categorizes patients based
on 3 risk factors: non-breast primary, non-bone metasta-
ses, and KPS ≤ 60. Group I includes patients with 0–1
risk factors, Group II with 2 risk factors, and group 3
with all three risk factors [14]. The TEACHH model as-
signs points based on the following risk factors:
non-breast or prostate primary, age > 60, ECOG per-
formance status 2–4, liver metastases, hospitalization
within 3 months of palliative RT consult, and 2 or more
prior palliative chemotherapy courses [12]. Patients with
0–1 risk factors are categorized in group A, 2–4 risk fac-
tors in group B, and 5–6 risk factors in group C.
Statistics
The Shapiro-Wilk test was used to evaluate normality of
continuous variables. Mann-Whitney U and Chi-squared
tests were used to compare patients who received RT
within 30 days of death (D30RT) and those who did not.
D30RT was calculated from the start of RT. Multivariate
analysis was used to identify factors associated with
D30RT. In our exploratory analysis of D30RT and inabil-
ity to complete the prescribed RT course, 16 clinical var-
iables were considered (Table 3); as such we performed
a Bonferroni correction and only 2-sided p-values less
than 0.003 were considered statistically significant. Sta-
tistics were performed using IBM SPSS, version 25
(SPSS; Chicago, IL).
Results
Five hundred and-eighteen patients were included in this
analysis. The median age at initial diagnosis was 60 years
(interquartile range (IQR) 50–68 years) (Table 1). The
median age at final RT course was 63 years (IQR 54–71
years). The median survival time from diagnosis to final
RT course was 28 months (IQR 11–53 months). Sixty-six
percent of patients (340/518) were Caucasian, while 14%
(74/518) were East Asian and 8.7% (45/518) African
American. Forty-nine percent of patients (254/518) had
metastatic disease at diagnosis. Forty-five percent of pa-
tients (231/511) had a KPS > 70 at the time of final RT
consult; KPS was not recorded at the time of consult-
ation in 8 patients. Fifty eight percent of patients (289/
500) were hospitalized within 3 months of RT consult.
The most common primary malignancies were lung
(26%, 137/518), breast (19%, 97/518) and prostate
(9.7%, 50/518). The most common treatment sites
were bone (57%, 293/518) and brain (28%, 146/518)
(Table 2). The median number of palliative chemo-
therapy regimens prior to RT was 1, though the range
was quite large (0–13 regimens) (IQR 0–3 regimens).
The median time from the start of last RT course to
death was 74 days (IQR 33–174 days). One hundred and
twenty-five patients (24%) died within 30 days of RT.
D30RT was associated with older median age at initial
diagnosis (63 vs. 59 years, p = 0.002) shorter interval
since diagnosis (14 vs. 31 months, p < 0.001), lower me-
dian KPS at consultation (50 vs. 70, p < 0.001), lower
median BMI (22 vs. 24, p = 0.001), and inpatient status
at consult (56% vs. 26%, p < 0.001) (Tables 3 and 4).
D30RT was associated with higher Chow and TEACHH
scores at the time of consult (p < 0.001 for both). D30RT
was associated with a greater likelihood of not complet-
ing the prescribed RT course compared to those who
lived longer than 30 days following start of RT (42% vs.
6%, p < 0.001). Despite poor outcomes, patients who
died within 30 days of RT were less likely to have hos-
pice involved in their care (44% vs. 71%, p = 0.001). The
rate of D30RT was not significantly different in patients
treated for brain metastases compared to bone metasta-
ses (42% vs. 29%, p = 0.27), or in patients who were older
at the time of RT (p = 0.04). On multivariate logistic re-
gression, D30RT was associated with older age at
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diagnosis (p < 0.001), older age at RT (p < 0.001), and
longer interval since initial diagnosis (p < 0.001).
Overall, 12% of patients (63/518) did not complete their
final RT course. Patients who did not complete radiation
were more likely to be inpatients at the time of RT con-
sultation (19% vs. 9%, p = 0.001) or have been hospitalized
within 3months of RT (16% vs. 8%, p = 0.005). Patients
who did not complete treatment were more likely to have
a KPS < 70 than those who completed treatment (84% vs.
51%, p < 0.001). Patients with a BMI < 25th percentile
were less likely to complete RT than those with a BMI ≥
25th percentile (62% vs. 76%, p = 0.02). Patients who did
not complete RT were prescribed more fractions than
those who completed RT (median 8 vs. 5 fractions, p =
0.001). Patients who did not complete RT had a shorter
period from last RT to death compared to those who did
complete treatment (median 18 vs. 73 days, p < 0.001). Pa-
tients unable to complete their last RT course were more
likely to be in TEACHH group C (24% vs. 11%, p < 0.001)
and Chow group III (55% vs. 32%, p < 0.001). Inability to
complete RT was not different in those receiving RT to
brain vs. bone metastases (p = 0.08). On multivariate logis-
tic regression, inability to complete RT was associated
with lower KPS (p < 0.001) and metastatic disease at diag-
nosis (p = 0.001).
Increased hospice enrollment was associated with a
longer interval since diagnosis (28 months vs. 21 months,
p = 0.04). Hospice was less likely to be involved when in-
patients were evaluated for RT compared to outpatients
(31% vs. 42%, p = 0.02). There was no association be-
tween age at diagnosis, age at RT, TEACHH or Chow
score, or KPS and hospice involvement. Patients enrolled
in hospice were less likely to die in a hospital setting
(6.2%) but rather at home (67%) or in a non-acute care
inpatient setting (27%, inpatient hospice unit or skilled
nursing facility) compared to those not enrolled in
Table 1 Patient characteristics
Variable Median (IQR) or
% (n, of 518)
Age at diagnosis 60 (50–68)
Percent female 46% (238)
Race
White 66% (340)
East Asian 14% (74)
African American 8.7% (45)
Southeast Asian 3.7% (19)
Asian NOS 3.7% (19)
Other (includes American
Indian, Pacific Islander)
4.1% (21)
Percent Hispanic 9.1% (47)
Survival time since
diagnosis (months)
28 (11–53)
Primary diagnosis
Lung 26% (137)
Breast 19% (97)
Prostate 9.7% (50)
Renal cell 5.8% (30)
Colorectal 5.8% (30)
Hepatocellular 3.8% (20)
Head and Neck 3.5% (18)
Skin 3.3% (17)
Othera 23% (119)
Metastatic at diagnosis 49% (254)
Site of metastases
Brain 47% (244)
Lung 55% (284)
Liver 40% (208)
Bone only 17% (90)
BMI last course 24(21–27)
KPS last consult 60 (50–80)
KPS > 70 45% (231/511)
Hospitalization within 3
months of RT consult
58% (289/500)
TEACHH scoreb Median survival,
months (IQR)
0–1 (Group A) 6.2% (32/450) 6 (2.8–11)
2–4 (Group B) 68% (352/450) 2.2 (1.0–5.0)
5–6 (Group C) 13% (66/450) 1.3 (0.5–2.3)
CHOW groupb
I 18% (92/510) 4.7 (2–11)
II 44% (227/510) 2.5 (1.0–5.6)
III 37% (191/510) 1.6 (0.7–2.7)
Hospice involved
Yes 47% (245)
Table 1 Patient characteristics (Continued)
Variable Median (IQR) or
% (n, of 518)
No 28% (147)
Unknown 24% (126)
Place of death
Inpatient, acute care 23% (120)
Home 29% (151)
Inpatient hospice, non-acute care 10% (52)
SNF (not hospice) 1.5% (8)
Unknown 36% (187)
aIncludes primary cancer of the liver, bile ducts, esophagus, ovary, pancreas,
meninges, endometrium, anus, lymph nodes, CNS, and pleura
bSome patients had incomplete information and thus TEACHH or Chow
groups could not be calculated (denominators 450 and 510 respectively).
Performance status at RT consult was the most commonly missing
information, but also hospitalizations within 3 months of RT consult and
number of prior palliative chemotherapy courses
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hospice (81% in a hospital, 13% at home, 6% non-acute
care inpatient) (p < 0.001).
Discussion
Radiotherapy can be very effective at palliating symp-
toms, however does not take effect immediately and can
entail multiple clinic visits over the treatment course. As
such, palliative RT should be used thoughtfully in pa-
tients with advanced cancer, with special attention to in-
tent, fractionation pattern, and goals of care for each
patient. This study applies validated, cancer-specific
prognostic tools to patients undergoing palliative radio-
therapy to sites of metastatic disease at a large academic
institution, and characterizes patients who received radi-
ation within 30 days of death. This study also highlights
clinical factors associated with incomplete RT courses,
which may be viewed as a quality indictor for selecting
an appropriate dose and fractionation regimen in appro-
priate patients.
Almost one-quarter of patients receiving palliative RT
in our series were treated within their last 30 days of life,
a rate higher than many published series [8, 9, 15–17].
This is likely in part due to the fact that our analysis was
restricted to patients receiving palliative RT to metasta-
ses (i.e. no palliation of the primary tumor) and excluded
patients treated with Gamma Knife radiosurgery, thereby
selecting for patients with greater intracranial metastatic
burden and/or poorer performance status. It has been
shown that D30RT may be higher in patients with more
advanced disease at diagnosis [18] or with certain pri-
mary tumors, particularly lung. Kapadia et al. demon-
strated that in patients with non-small cell lung cancer,
those who were metastatic at diagnosis were twice as
likely to undergo radiation at the end of life [18]. Even
among patients with metastatic disease, those with mul-
tiple metastases were 75% more likely to undergo radi-
ation within 2 weeks of death than patients with a single
site of metastatic disease. Murphy et al. demonstrated
that patients with primary lung cancer had an odds ratio
for death within 1 month of completing RT of 3.8 com-
pared to patients with prostate cancer [19]. Consistent
with our data, the rate of D30RT may be high in patients
receiving palliative RT to bone or brain metastases (26
and 23%, respectively) [10] [20]. However, a very low
rate of D30RT is not necessarily ideal, as this may reflect
treatment being withheld from patients who may other-
wise benefit from palliative-directed RT. On the other
end of the spectrum, a high D30RT may suggest overly
aggressive treatment or selection of RT fractionation reg-
imens that are too protracted in duration and misaligned
with patient-specific needs.
Forty-two percent of patients who received RT within
30 days of death in our cohort did not complete their
planned RT course, consistent with the literature [21].
This may be due, in part, to the fact that prognostication
at the end of life is a difficult task and physicians are
often overly optimistic [22, 23]. Several tools have been
developed to assist in estimating life expectancy. The
palliative prognostic index uses palliative performance
status, which is strongly correlated with, and can be used
interchangeably with, KPS, oral intake, and clinical
symptoms such as dyspnea, delirium, and edema to esti-
mate life expectancy in patients receiving palliative care
[24, 25], and performs comparably to similar scores that
also take into account white blood cell count, lympho-
cyte percentage, or delirium in cancer patients [26]. A
nomogram has also been created that includes time
since diagnosis, performance status, albumin, lactate de-
hydrogenase, and lymphocyte count to predict 15, 30,
and 60-day survival [27].
These tools, however, do not evaluate prognosis using
cancer specific characteristics. The TEACHH score and
Chow model are two prognostic tools that have been de-
veloped to predict life expectancy in patients with ad-
vanced cancer [12, 13]. Both take into account KPS and
primary diagnosis; the Chow model also incorporates
non-bone metastases while the TEACHH score includes
prior chemotherapy, recent hospitalizations, and specif-
ically hepatic metastases. The TEACHH score catego-
rizes patients into three groups (A, B, and C) with
distinct survival times from the start of RT (19.9 months,
5 months, and 1.7 months, respectively) [12]. The Chow
“number of risk factors” model categorizes patients into
Table 2 Summary of RT
Characteristic Median (IQR) or
% (n, of 518)
Palliative course # 1 (1–2)
Age at RT 63 (54–71)
Prescribed fractions 5 (4–10)
1 17% (89)
2–4 9.6% (50)
5 32% (167)
6–9 3.5% (18)
10 34% (177)
> 10 3.3% (17)
Treatment site
Bone 57% (293)
Brain 28% (146)
Lung 2.9% (15)
Node 1.7% (9)
Othera 11% (55)
Incomplete RT course 12% (63)
Time from start of last RT course to death (days) 74 (33–174)
aIncludes soft tissue and visceral metastases
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three groups (I, II, and III) with median survival times of
approximately 15, 6.5, and 2.5 months respectively
[13]. A recently published "NEAT" model is similar to
the TEACHH score but also incorporates albumin
levels to yield four prognostic groups with median sur-
vivals of 24.9, 14.8, 4.0, and 1.2 months [14].
In our cohort, median survival was shorter than esti-
mated across all TEACHH and Chow groups (Table 1).
This may reflect use of palliative RT earlier in the dis-
ease course among the TEACHH cohort, with a shorter
time from diagnosis to RT consult (1.8 months,
calculated as the sum of time from diagnosis to metasta-
sis and from metastasis to RT consult), compared to 28
months in our cohort. Patients in our cohort were also
more likely to have received prior palliative RT than pa-
tients in the TEACHH cohort (44% vs. 12.5%). Com-
pared to the Chow training set, our cohort had a
substantially lower percentage of patients with
bone-only metastases (17% vs. 29%), which may translate
into a more significant disease burden and thus poorer
prognosis in our patients. As only 45% of patients (30/
66) in TEACHH group C and 36% of patients (68/191)
Table 3 Characteristics of patients and treatment in those who died within 30-days of RT (D30RT) and those who did not (D>30RT)
D30RT (median (IQR) or
% (proportion)b)
D>30RT (median (IQR) or
% (proportion)b))
Chi-squared or
p-value°
Age at diagnosis 63 (52–70) 59 (47–67) 0.002
Age at RT 64 (55–73) 62 (52–70) 0.04
Gender, % female 42% (52/125) 47% (184/393) 0.35
% Hispanic 5.8% (7/119) 11% (40/381) 0.15
Survival time (months, diagnosis to RT) 14 (5–38) 31 (14–59) < 0.001
KPS at RT consult 50 (20–70) 70 (50–80) < 0.001
BMI at RT consult 22 (IQR 20–25) 24 (21–27) 0.001
Primary diagnosis breast/prostate 18% (22/125) 32% (124/393) 0.003
Treatment site
Bone 53% (66/125) 77% (227/393) 0.35
Brain 34% (43/125) 26% (103/393) 0.09
Lung 4% (5/125) 3% (10/393)
Othera 9%(11/125) 13% (53/393)
Hospitalization within 3 months of consult 78% (97/125) 51% (192/375) < 0.001
Metastatic at diagnosis 50% (62/125) 50% (191/388) 0.94
Sites of metastases
Non-bone 90% (112/125) 80% (315/392) 0.08
Brain 51% (63/124) 47% (181/387)
Lung 62% (78/125) 53% (206/390)
Liver 50% (62/125) 38% (146/386)
Prescribed fractionsc 5 (3–10) 5 (4–10) 0.14
TEACHH Group < 0.001
A 1.6% (2/124) 9% (30/326)
B 74% (92/124) 80%(260/326)
C 24%(30/124) 11%(36/326)
Chow group < 0.001
I 3% (5/124) 23% (87/386)
II 41% (51/124) 46% (176/386)
III 55% (68/124) 32% (123/386)
Inpatient consult 56% (70/125) 26% (103/393) < 0.001
Hospice involved 44% (54/122) 71% (191/270) < 0.001
°values in bold are statistically significant given our adjusted α of 0.003
aIncludes soft tissue and visceral metastases
bDenominators reflect missing data and thus are not all 125 (D30RT) or 393 (D>30RT)
cPrescribed fractions was not considered in the Bonferroni correction, as this is a decision made by the treating radiation oncologist based on clinical variables
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in Chow group III died within 30 days of RT, the inte-
grated prognostic tools currently available do not appear
sufficiently specific to identify patients at risk for
imminent death at the time of RT consultation.
In the United States, there is a tendency to prescribe
more protracted treatment regimens in patients with
longer anticipated survival [28]. Initial concern regarding
durability of control following short course RT may have
stemmed from higher re-treatment rates seen following
single-fraction RT in RTOG 9714 [29], however the
Dutch Bone Metastases Study showed that re-irradiation
occurred at a higher rate among non-responders and at
lower pain scores in the cohort that received single
fraction RT compared to the cohort that received
multi-fraction RT, despite similar overall response rates,
time to, and duration of response [3]. This suggests that
higher retreatment rates after single fraction RT may be
due to physician views on the safety of retreatment.
A large body of evidence has demonstrated that single
fraction RT courses are as effective as more protracted
courses with regard to onset of symptomatic improve-
ment, duration of relief, proportion of patients experien-
cing improvement, and subsequent quality of life in
patients with bone metastases [1, 30, 31]. Similarly, no
overall survival benefit has been demonstrated with lon-
ger RT courses in the treatment of malignant cord com-
pression or brain metastases [7, 32, 33]. However, a
survey of practicing members of the American Society
of Radiation Oncology suggests the most common
palliative fractionation pattern in the United States re-
mains 30 Gy in 10 fractions; single-fraction treatment is
more common among those practicing in Canada,
Australia, and New Zealand [34]. In a survey of radiation
oncologists practicing within the Veterans Healthcare
Administration, physicians who had been in practice for
more than 10 years were less likely to offer single frac-
tion RT compared to those with fewer years in practice
(63% vs. 90%, p = 0.01) suggesting there may be shifts in
practice patterns over time [35]. Of note, this survey also
found that those who had ever worked in private prac-
tice were less likely to offer single fraction RT (64% vs.
88%, p = 0.03), suggesting that practice patterns may be
influenced by practice setting.
Patients receiving RT at the end of life are increasingly
receiving more advanced treatment modalities, with a
decrease in the proportion receiving 2D RT from 75 to
33% from 2000 to 2009 [36]. Use of 3D RT increased
from 27 to 59%, and use of IMRT increased from 0 to
6.2% over the same period. As patients live longer with
advanced cancer, and potentially receive more palliative
RT courses, there may be indications for such tech-
niques, including retreatment or treatment in close
proximity to prior fields. However more advanced plan-
ning techniques require more planning and quality as-
surance time, which is already limited for patients with
poor prognosis.
When used appropriately, palliative RT in patients
with advanced cancer may relieve symptoms and pre-
serve quality of life. However radiotherapy remains a
local treatment. Patients with advanced cancer suffer
from a broad range of symptoms that RT may not be
able to address, such as depression, anxiety, or anorexia/
cachexia. Furthermore RT, depending on the treatment
site, may cause symptoms that can, in turn, diminish
quality of life, including fatigue, nausea, or xerostomia.
As such, it is critical that patients receive palliative care
services early in their disease course, in parallel with dis-
ease directed care. Palliative care should start with the
primary interdisciplinary oncology team, with referrals
to palliative care specialists if patient needs are complex;
this approach is supported by the NCCN [37], WHO
[38], and ASCO [39]. There is level I evidence support-
ing early integration of palliative care with regard to pa-
tient reported quality of life [40], as well as duration of
life [41].
Earlier integration of palliative care fits with a growing
notion of primary palliative care—that is, a fundamental
level of palliative care proficiency that should be ex-
pected of all clinicians, which can be augmented by pal-
liative care specialists as needed [42]. Indeed, given
almost half of RT courses are palliative in nature, radi-
ation oncologists should also consider themselves pallia-
tive care providers and co-manage symptoms with other
Table 4 Risk of death within 30 days based on clinical variables
Clinical variable Risk of death within 30 days,
% (proportion)
Age (years) at RT
> 60 26% (76/294)
> 70 30% (42/142)
> 80 30% (9/30)
KPS < 70 at RT 33% (91/280)
Treatment site
Bone 23% (67/294)
Brain 29% (42/145)
Hospitalized within
3 months of RT consult
34% (97/289)
TEACHH group
A 6% (2/32)
B 26% (92/352)
C 45% (30/66)
CHOW group
I 5%(5/92)
II 22% (51/227)
III 36% (68/191)
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providers. Furthermore, as palliative care needs vary
substantially throughout a patient’ disease course [43],
they should be reassessed at regular intervals in all can-
cer patients [39].
This study is limited in that data was obtained retro-
spectively and may be incomplete, particularly for pa-
tients who were seen prior to the transition to electronic
medical records or who received care at other institu-
tions. In particular, data regarding prior chemotherapy
was often incomplete; while we typically had records
documenting the regimen, we often lacked the total
number of cycles received. Documentation of the spe-
cific indication for palliative RT was inconsistent and
highly heterogeneous, which made further analysis diffi-
cult. Furthermore, due to the retrospective nature of the
data, our information regarding symptomatic improve-
ment and quality of life in patients undergoing palliative
radiation at the end of life is limited. Patients treated at
our institution may have more advanced disease than
those treated at other institutions, particularly patients
enrolled in Phase I trials or seen in the inpatient setting.
The exploratory nature of this analysis must also be em-
phasized. We have attempted to reduce the risk of Type
I error using a Bonferroni correction, however it remains
that these analysis were conducted without a specific
predetermined hypothesis. Additionally, a significant
proportion of patients not enrolled in hospice were be-
ing followed by palliative care services. We were unable
to more thoroughly assess patterns of palliative care re-
ferrals or quantify use of palliative care services in this
cohort due to changes in referral codes over time. How-
ever it is likely that end-of-life and goals-of-care discus-
sions were occurring more often than it would seem
solely based on the rate of hospice enrollment.
Conclusion
A substantial proportion of patients with advanced can-
cer undergo palliative RT within 30 days of death, sug-
gesting that there remains a great deal of work to be
done to improve the quality of care delivered at the end
of life. Palliative RT must align with patient-directed
goals of care, and offer maximal palliation while main-
taining quality of remaining life. Prognostication for in-
dividual patients with advanced cancer continues to be
is quite difficult, and the current tools available are not
specific for patients at imminent risk of death. All pa-
tients with advanced cancer should receive multidiscip-
linary palliative care from their treating oncologists and,
as needs become more complex, palliative care special-
ists are of great value.
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